drugset / Trial / NCT00364572

Efficacy of Epidural Etanercept in the Treatment of Sciatica

NCT00364572

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Tumor necrosis factor (TNF)-alpha has been strongly implicated as a major contributing factor for the development of radiculopathy. In animal studies, the application of TNF-alpha to nerve roots results in pain behavior indicative of radiculopathy. The use of TNF-alpha inhibitors (etanercept and infliximab) have been shown to prevent this pain behavior. Open-label studies in humans have shown both etanercept and infliximab provide excellent, long-term relief in patients with acute radiculopathy from herniated disc. However, a recent placebo-controlled study failed to demonstrate any significant difference from placebo. The investigators have already established the safety of neuraxial etanercept in a trial that has just been completed (not yet published). The objective of this study is to determine whether small doses of epidural etanercept, an anti-TNF-a medication, is an effective treatment for LBP caused by nerve root irritation (i.e., radiculopathy).

Timeline

Start
2006-05
Primary completion
2007-12
Completion
2007-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 2 mg Other
Subject Etanercept Protein / enzyme biologic 4 mg Other
Subject Etanercept Protein / enzyme biologic 6 mg Other

Indications